<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04021368</url>
  </required_header>
  <id_info>
    <org_study_id>CLI120-001</org_study_id>
    <nct_id>NCT04021368</nct_id>
  </id_info>
  <brief_title>RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase Ib Study of RVU120 (SEL120) in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ryvu Therapeutics SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ryvu Therapeutics SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-human study will evaluate RVU120 (SEL120), a novel small molecule CDK8/19&#xD;
      inhibitor, in patients with Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic&#xD;
      Syndrome (HR-MDS), in terms of selection of the recommended dose for further clinical&#xD;
      development and assessment of safety, tolerability, preliminary anti-leukemic activity, as&#xD;
      well as pharmacokinetic and pharmacodynamic profiles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will determine the recommended phase II dose (RP2D) and safety of RVU120 (SEL120)&#xD;
      given as monotherapy over a range of dose-levels, following a closely controlled dose&#xD;
      escalation study design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dose escalating Cohorts with a safety expansion Cohort</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended dose (RD)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>The RD will be determined using all available data, which will include dose limiting toxicities (DLTs) and other toxicities, signs of anti-leukemic activity, pharmacokinetic and pharmacodynamic characteristics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (Safety and Tolerability)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Safety and tolerability profile will be assessed by Common Terminology Criteria for Adverse Events v5.0 and summarized by type, frequency, and severity of adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Maximum Observed Concentration (C[max])</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Pharmacokinetic profile of SEL120 will be characterized using the Maximum Observed Concentration (C[max]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Terminal Half-life (t[1/2])</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Pharmacokinetic profile of SEL120 will be characterized using the Terminal Half-life (t[1/2]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Area Under the Curve (AUC)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Pharmacokinetic profile of SEL120 will be characterized using the Area Under the Curve (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Pharmacokinetic profile of SEL120 will be characterized using the Volume of Distribution at Steady State (Vss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-leukemic activity</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Anti-leukemic activity will be assessed by AML or MDS Response Criteria (Döhner et al., 2017, or Cheson et al., 2006, respectively).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AML surface markers</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Pharmacodynamic profile of SEL120 will be characterized using immunophenotyping of AML surface markers by exploratory assay.</description>
  </other_outcome>
  <other_outcome>
    <measure>Phosphorylated protein levels in AML blasts</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Pharmacodynamic profile of SEL120 will be characterized using phosphorylated protein levels in AML blasts by exploratory immunoassay.</description>
  </other_outcome>
  <other_outcome>
    <measure>Transcriptomic profile changes in AML blasts</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Pharmacodynamic profile of SEL120 will be characterized using transcriptomic profile changes in AML blasts by exploratory next generation sequencing.</description>
  </other_outcome>
  <other_outcome>
    <measure>Genetic profile changes in AML blasts</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Pharmacodynamic profile of SEL120 will be characterized using genetic profile changes in AML blasts by next generation sequencing.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>High-risk Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>RVU120(SEL120)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first part of the study consists of dose-escalation cohorts where patients will receive ascending doses of RVU120(SEL120) to determine the recommended dose (RD) for further clinical development. The second part of the study is an enrichment cohort where additional 6 to 20 patients will be treated with RVU120(SEL120) to support the evaluation of the RD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RVU120(SEL120)</intervention_name>
    <description>RVU120(SEL120) will be administered as a single oral dose every other day (q.o.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.</description>
    <arm_group_label>RVU120(SEL120)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All the following criteria must be met for a patient to be eligible for the study:&#xD;
&#xD;
          1. Written informed consent provided prior to any study-related procedure.&#xD;
&#xD;
          2. Age ≥18 years.&#xD;
&#xD;
          3. AML diagnosis according to the 2016 World Health Organisation (WHO) classification&#xD;
             (Arber et al. 2016) with relapsed or refractory disease who have received no more than&#xD;
             3 prior lines of therapy and with no available therapy who have exhausted the&#xD;
             applicable standard of care; or Myelodysplastic Syndrome (MDS) diagnosis according to&#xD;
             the 2016 WHO classification (Arber et al. 2016) with high-risk disease per the Revised&#xD;
             International Prognostic Scoring System and with relapsed or refractory disease, who&#xD;
             have received no more than 3 prior lines of therapy and with no available therapy who&#xD;
             have exhausted the applicable standard of care.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.&#xD;
&#xD;
          5. Patients must have been off anti-cancer treatment for 2 weeks or 5 half-lives,&#xD;
             whichever is longer. Note: Hydroxyurea is exempted if used to reduce total white blood&#xD;
             cell (WBC) count (see below); radiation must have been completed at least 4 weeks&#xD;
             prior to first dose of study drug.&#xD;
&#xD;
          6. Patients must have recovered from the toxic effects of previous treatments to at least&#xD;
             Grade 1, for neurotoxicity or alopecia to Grade 2.&#xD;
&#xD;
          7. Clinical laboratory parameters as follows:&#xD;
&#xD;
               1. Peripheral white blood cell (WBC) count, no upper limit at Screening, but must be&#xD;
                  &lt;10x10^9/L on Day 1 prior to first dose of study drug. Note: Patients with&#xD;
                  excessive blasts may be treated with hydroxyurea until 2 days prior to first dose&#xD;
                  of study drug to reduce WBC;&#xD;
&#xD;
               2. Platelet count &gt;10,000/µL; Platelet transfusion prior to first dose is permitted&#xD;
&#xD;
               3. Serum albumin ≥ 30g/L (3.0g/dL)&#xD;
&#xD;
               4. Normal coagulation (elevated INR, prothrombin time or APTT &lt;1.3 x ULN&#xD;
                  acceptable);&#xD;
&#xD;
               5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3x the upper&#xD;
                  limit of normal (ULN);&#xD;
&#xD;
               6. Total bilirubin ≤1.5 x ULN; and&#xD;
&#xD;
               7. Creatinine clearance ≥60 mL/min (Cockcroft-Gault formula)&#xD;
&#xD;
               8. Urine protein ≤ 2+ (as measured by dipstick) or ≤100 mg/24 hours urine&#xD;
&#xD;
          8. Adequate cardiac function confirmed by left ventricular ejection fraction ≥40% as per&#xD;
             echocardiography or MUGA (Multiple Gated Acquisition) scan.&#xD;
&#xD;
          9. Life expectancy of at least 12 weeks.&#xD;
&#xD;
         10. For females of childbearing potential (FCBP), a negative pregnancy test must be&#xD;
             confirmed before enrolment. FCBP must commit to using two medically accepted forms of&#xD;
             effective contraception during study participation and until 6 months after the last&#xD;
             dose of study drug. Note: Where oral contraceptives are considered, please contact the&#xD;
             Medical Monitor. Females must also refrain from donating blood during the same&#xD;
             time-period.&#xD;
&#xD;
         11. For males, an effective barrier method of contraception must be used during study&#xD;
             participation until 6 months after the last dose of study drug, if the patient is&#xD;
             sexually active with a FCBP. Males must also refrain from donating blood or sperm&#xD;
             during the same time-period.&#xD;
&#xD;
         12. Investigator considers the patient to be suitable for participation in the clinical&#xD;
             study by assessing that they:&#xD;
&#xD;
               -  Understand the requirements of the clinical study and can give informed consent;&#xD;
&#xD;
               -  Can comply with study medication dosing requirements and all study-related&#xD;
                  procedures and evaluations; and&#xD;
&#xD;
               -  Are not considered to be potentially unreliable and/or not cooperative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any of the following will exclude a patient from enrolment:&#xD;
&#xD;
          1. Active central nervous system (CNS) leukemia.&#xD;
&#xD;
          2. Previous treatment with CDK8-targeted therapy.&#xD;
&#xD;
          3. Patients who have undergone major surgery within 28 days prior to first dose of study&#xD;
             drug.&#xD;
&#xD;
          4. Hematopoietic stem cell transplant within 120 days prior to first dose of study drug.&#xD;
&#xD;
          5. Active Grade 2-4 acute graft versus host disease (GVHD), active moderate-to-severe&#xD;
             chronic GVHD, or requirement for systemic immunosuppressive medications for GVHD.&#xD;
&#xD;
          6. Evidence of ongoing and uncontrolled systemic bacterial, fungal, or viral infection&#xD;
             and acute inflammatory conditions (including pancreatitis).&#xD;
&#xD;
          7. Known seropositivity or history of active viral infection with human immunodeficiency&#xD;
             virus (HIV) or known active positive test of /or known active diagnosis of COVID-19&#xD;
             viral infection.&#xD;
&#xD;
          8. Ongoing significant liver disease such as cirrhosis, drug-induced liver injury, active&#xD;
             hepatitis or chronic persistent hepatitis B and/or C.&#xD;
&#xD;
          9. Impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
             significantly alter the absorption of RVU120 (SEL120) (e.g. active inflammatory bowel&#xD;
             disease, ulcerative disease, malabsorption syndrome, short bowel syndrome,&#xD;
             uncontrolled nausea, vomiting or diarrhea).&#xD;
&#xD;
         10. Ongoing drug-induced pneumonitis.&#xD;
&#xD;
         11. Concurrent participation in another investigational clinical trial.&#xD;
&#xD;
         12. Taking any medications, herbal supplements or other substances (including smoking)&#xD;
             that are known to be strong inhibitors or inducers of CYP1A2 or that can prolong Q&#xD;
             wave to T wave (QT) interval and/or cause torsade de pointes within less than 2 weeks&#xD;
             or 5 half-lives, whichever is shorter, prior to first dose of study drug. Any&#xD;
             exception should be discussed with the Study Sponsor Medical Director.&#xD;
&#xD;
         13. Significant cardiac dysfunction defined as myocardial infarction within 12 months of&#xD;
             first dose of study drug, New York Heart Association (NYHA) Class III or IV heart&#xD;
             failure, uncontrolled dysrhythmias, or poorly controlled angina.&#xD;
&#xD;
         14. Currently taking drugs that are documented, in the drug package insert, to have a risk&#xD;
             of causing prolonged QTc or torsades de pointes (TdP) within 2 weeks or 5 half-lives,&#xD;
             whichever is shorter, prior to first dose of study drug. Please also consult the&#xD;
             following&#xD;
&#xD;
             Credible Meds web page:&#xD;
&#xD;
             https://crediblemeds.org/index.php/login/dlcheck (Appendix F). Any exception should be&#xD;
             discussed with the Study Sponsor Medical Director&#xD;
&#xD;
         15. Personal or family history of serious ventricular arrhythmia, or QT interval corrected&#xD;
             for heart rate (QTc) ≥450 ms (Bazett's formula).&#xD;
&#xD;
         16. Any other prior or current medical condition, intercurrent illness, surgical history,&#xD;
             physical or electrocardiogram (ECG) findings, laboratory abnormalities, or extenuating&#xD;
             circumstance (e.g. alcohol or drug addiction) that, in the Investigator's opinion,&#xD;
             could jeopardize patient safety or interfere with the objectives of the study.&#xD;
&#xD;
         17. Prior history of malignancies other than AML or MDS, unless the patient has been free&#xD;
             of the disease for 5 years or more prior to Screening. Exceptions to the ≥5-year time&#xD;
             limit include history of the following:&#xD;
&#xD;
               1. basal cell carcinoma of the skin;&#xD;
&#xD;
               2. non-metastatic squamous cell carcinoma of the skin;&#xD;
&#xD;
               3. carcinoma in situ of the cervix;&#xD;
&#xD;
               4. carcinoma in situ of the breast;&#xD;
&#xD;
               5. carcinoma in situ of the bladder; and&#xD;
&#xD;
               6. incidental histological finding of prostate cancer (Tumor/Node/Metastasis [TNM]&#xD;
                  stage of T1a or T1b).&#xD;
&#xD;
         18. Pregnant or breast-feeding females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Head of Clinical Operations</last_name>
    <phone>+48 538 898 766</phone>
    <email>clinicaltrials@ryvu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrence J Bradley, MD</last_name>
    </contact>
    <investigator>
      <last_name>Terrence J Bradley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Solomon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Scott Solomon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille N. Abboud, MD</last_name>
    </contact>
    <investigator>
      <last_name>Camille N. Abboud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Donnellan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gautam Borthakur, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gautam Borthakur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Zaucha, MD</last_name>
      <phone>+48 58 584 43 40</phone>
    </contact>
    <investigator>
      <last_name>Jan Zaucha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warsaw</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Lech-Marańda, MD</last_name>
      <phone>+48 22 3496100</phone>
    </contact>
    <investigator>
      <last_name>Ewa Lech-Marańda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>CDK8/19 Inhibitor</keyword>
  <keyword>RVU120 (SEL120)</keyword>
  <keyword>Clinical Trial, Phase Ib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

